Dexcom G7 Review: The Complete 2025 Guide

What Is the Dexcom G7?

The Dexcom G7 is a continuous glucose monitoring (CGM) system manufactured by Dexcom, Inc. It measures interstitial glucose levels every five minutes — 288 readings per day — without requiring fingerstick calibration. The G7 launched in the United States in March 2023 and has rapidly become the most prescribed CGM for people with Type 1 diabetes, and one of the most popular for Type 2 as well.

Unlike older CGM systems that required a separate reusable transmitter snapped onto a disposable sensor, the G7 combines both components into a single, all-in-one wearable pod. This design is 60% smaller than the Dexcom G6, making it one of the most discreet medical wearables available. The sensor is worn on the upper arm or abdomen and lasts 10 days, with an additional 12-hour grace period built in — giving users more flexibility than any previous Dexcom generation.

According to Dexcom's published clinical data, the G7 achieves a Mean Absolute Relative Difference (MARD) of 8.2% — a figure that represents how closely the CGM's readings track a laboratory reference standard. Lower MARD equals higher accuracy. The G7's 8.2% MARD is the best published figure for any consumer-grade CGM as of 2025.

How Does the Dexcom G7 Work?

The G7 uses electrochemical biosensor technology to measure glucose in the interstitial fluid beneath your skin. Here's the step-by-step process:

1. Insertion: The all-in-one sensor pod is applied to the upper arm (recommended) or abdomen using a one-button auto-inserter. The needle is removed immediately; only a thin, flexible filament remains under the skin.
2. Warmup: The G7 has the shortest warmup period of any major CGM — just 30 minutes — compared to 60 minutes for the G6 and 60 minutes for the Libre 3.
3. Glucose measurement: Every 5 minutes, the sensor measures glucose in the fluid surrounding your cells and transmits readings via Bluetooth to your receiver or smartphone app.
4. Alerts and trends: The Dexcom G7 app displays your current glucose, a trend arrow (rising, falling, stable), and can alert you to highs, lows, and urgent lows before symptoms appear.
5. Data sharing: Through the Dexcom Follow app, caregivers and family members can view glucose data in real time — a critical safety feature for children and elderly patients.

No fingerstick calibration is required under normal circumstances. The FDA cleared the G7 for use as a standalone therapeutic CGM, meaning dosing decisions can be made from CGM data alone — without confirming with a blood glucose meter.

Dexcom G7 Accuracy: What the Research Shows

Accuracy is the most important metric for any CGM. The G7's published clinical accuracy data is exceptional:

• Overall MARD: 8.2% (lower is better)
• In hypoglycemic range (<70 mg/dL): 9.5% MARD
• In hyperglycemic range (>180 mg/dL): 8.0% MARD
• Percentage of readings within 20% of reference value: 87%
• Percentage within 20 mg/dL of reference (in low range): 98.5%

A 2023 study published in Diabetes Technology & Therapeutics confirmed the G7's real-world accuracy closely matched its clinical trial results — which is notable, since many devices perform better in controlled settings than in daily life. The study also found the G7 performed consistently across all sensor wear days, including Day 1 (which is often the least accurate day for CGMs).

For context: a MARD below 10% is generally considered clinically acceptable for therapeutic CGM use. The G7 at 8.2% provides a meaningful margin of safety that older devices — including the original Dexcom G5 (9.0% MARD) and the FreeStyle Libre 2 (9.3% MARD) — do not match.

Dexcom G7 vs G6 vs FreeStyle Libre 3: Complete Comparison

Verdict on the comparison: The FreeStyle Libre 3 wins on price and wear duration. The Dexcom G7 wins on ecosystem integration, warmup speed, Apple Watch support, and pump compatibility. For users on closed-loop insulin delivery systems or those who rely on smartphone alerts for hypoglycemia management, the G7 is the clear choice.

Setting Up the Dexcom G7: Step-by-Step Guide

What's in the Box

• Dexcom G7 sensor and integrated transmitter (all-in-one pod)
• One-button auto-inserter
• Adhesive patch (pre-applied)
• Quick start guide

Setup Instructions

1. Download the Dexcom G7 app on your iOS or Android smartphone and create or log in to your Dexcom account.
2. Choose your insertion site: The upper arm (back of the arm, tricep area) is FDA-approved and most commonly recommended. The abdomen is also approved for adults. Children ages 2–17 may use the upper buttocks.
3. Clean and dry the site: Use an alcohol wipe and allow it to dry completely — at least 60 seconds. Moisture under the sensor is the #1 cause of early adhesive failure.
4. Apply the sensor pod: Remove the adhesive backing, position the pod flat against your skin, and press the orange button firmly until you hear two clicks.
5. Pair with your phone: Open the G7 app, tap "Start New Sensor," and scan the QR code on the sensor packaging. Bluetooth pairing happens automatically.
6. Wait 30 minutes: The G7 will display a countdown timer. After warmup, readings begin automatically.
7. Apply an overpatch (recommended): For swimmers, athletes, or anyone active, apply a waterproof overpatch immediately after sensor insertion to prevent early detachment.

Best Sensor Placement Sites for the Dexcom G7

Placement matters significantly for both accuracy and adhesion. Here are the evidence-based best practices:

Recommended Sites (FDA-Approved)

• Back of the upper arm (tricep area): Best accuracy, least movement artifact, most discreet. Most clinicians' first recommendation.
• Abdomen (for adults): Good accuracy, easy to self-apply, familiar site for insulin users. Avoid the waistband area and within 3 inches of the navel.
• Upper buttocks (ages 2–17 only): Recommended in Dexcom's pediatric labeling.

Placement Tips to Maximize Accuracy

• Rotate sites — using the same spot repeatedly causes skin irritation and reduced accuracy.
• Avoid areas with scar tissue, tattoos, or lipohypertrophy (fatty lumps from repeated insulin injections).
• Apply on flat, relatively hairless skin for best adhesion.
• In cold weather, warm the skin with your hand before applying — cold skin can cause poor initial adhesion.

Accessories You Need: Overpatches for the G7

The Dexcom G7's integrated design is elegant, but its adhesive — while adequate for most users in normal conditions — can struggle during intense exercise, swimming, hot showers, or high-humidity environments. This is the most commonly reported real-world complaint about the G7, and the solution is straightforward: waterproof overpatches.

An overpatch is a thin, transparent adhesive patch applied over the sensor to dramatically extend adhesion life and prevent the sensor from being knocked off. They are particularly important for:

• Swimmers and water sports athletes
• People who sweat heavily (outdoor workers, gym users)
• Children and teenagers (active lifestyle, physical contact sports)
• Anyone who showers frequently throughout the day

Troubleshooting Common Dexcom G7 Problems

"Signal Loss" or Dropped Bluetooth Connection

The G7 uses Bluetooth Low Energy and requires your phone to be within approximately 20 feet. Common causes of signal loss include: walking away from your phone, certain phone cases that block Bluetooth, or being near strong electromagnetic interference (MRI rooms, industrial equipment). Solution: keep your phone within range, and consider a Dexcom receiver as a backup display.

Sensor Falling Off Early

This is the most reported issue. Solutions: ensure the skin is completely dry before application, apply an overpatch immediately after insertion, and avoid lotions or oils near the site for 24 hours before applying a new sensor.

Inaccurate Readings on Day 1

Some users notice slightly higher variability on the first day of sensor wear. This is normal as the sensor acclimates to interstitial fluid. The G7 typically stabilizes by hour 4–6 of Day 1. If readings remain inconsistent, compare to a fingerstick meter — if there is more than a 20% discrepancy, contact Dexcom support for a replacement sensor.

"Urgent Low" Alarm False Alarms

The Urgent Low alarm (fixed at 55 mg/dL) cannot be turned off — this is an FDA safety requirement. If you're experiencing false urgent lows, check your sensor placement site and ensure you're not compressing the sensor during sleep. Compression can temporarily reduce interstitial fluid flow and cause falsely low readings.

Insurance Coverage and Cost: Medicare, FSA, and HSA

Medicare Part B Coverage

The Dexcom G7 is covered under Medicare Part B as durable medical equipment (DME) for beneficiaries who meet specific criteria:

• Diagnosed with diabetes (Type 1 or Type 2)
• Treated with insulin, OR at high risk for hypoglycemia
• A face-to-face visit with a prescribing provider documented within 6 months

Under Part B, Medicare covers 80% of the approved cost; your supplemental insurance (Medigap) or 20% co-pay applies. Most Medicare beneficiaries pay little to nothing out of pocket for the G7 with proper supplemental coverage.

Private Insurance

Most major commercial insurance plans (Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare) cover the Dexcom G7 with a prescription. Coverage tiers and copays vary significantly by plan. As of 2025, Dexcom estimates that over 99% of privately insured Americans with diabetes have access to a CGM benefit.

FSA and HSA Eligibility

The Dexcom G7 and all related supplies — including sensors, receivers, and overpatches — are FSA and HSA eligible as medical expenses. This applies to supplies purchased at pharmacies and online retailers including mdsdiabetes.com.

Cash Pay and Manufacturer Savings

Without insurance, the G7 costs approximately $349/month for three 10-day sensors. Dexcom offers a savings program for commercially insured patients that may reduce out-of-pocket costs to as little as $10/month. An uninsured or underinsured patient should contact Dexcom directly at 1-888-738-3646 to discuss the Dexcom ACCESS program.

Who Should Use the Dexcom G7?

Best Candidates for the G7

• Type 1 diabetes: The G7 is considered standard of care for Type 1. Its integration with automated insulin delivery (AID) systems like the Omnipod 5 and Tandem t:slim X2 makes it essential for closed-loop management.
• Type 2 diabetes on insulin: Anyone taking multiple daily injections or using an insulin pump benefits substantially from real-time glucose data.
• Hypoglycemia unawareness: For people who don't feel their blood sugar dropping (a dangerous condition called hypoglycemia unawareness), the G7's customizable alerts can be lifesaving.
• Pregnant women with diabetes: Real-time CGM is associated with better pregnancy outcomes in both Type 1 and gestational diabetes. The G7 is FDA-cleared for use during pregnancy.
• Active adults and athletes: The small profile, 30-minute warmup, and Apple Watch integration make it ideal for people with active lifestyles.

Who May Prefer an Alternative

• Budget-conscious Type 2 patients not on insulin: The FreeStyle Libre 3 at ~$129/month offers excellent accuracy at a lower price point for those not requiring real-time alerts.
• Non-smartphone users: While the G7 receiver is available separately, users who prefer not to carry any device may find the Libre system (which can be scanned on demand) simpler.

Final Verdict: Is the Dexcom G7 the Best CGM in 2025?

For the majority of people with insulin-requiring diabetes, yes — the Dexcom G7 is the best CGM available in 2025. Its combination of 8.2% MARD accuracy, 30-minute warmup, all-in-one compact design, Apple Watch compatibility, closed-loop pump integration, and robust alert system creates an ecosystem that no competitor has fully matched.

The primary practical concern — adhesive durability — is easily solved with quality waterproof overpatches, available affordably at mdsdiabetes.com. Once that limitation is addressed, the G7 delivers on its promise of reliable, discreet, always-on glucose monitoring that genuinely improves quality of life and clinical outcomes.

Multiple peer-reviewed studies have confirmed that CGM use — particularly with real-time alert systems like the G7 — is associated with significant reductions in HbA1c, fewer hypoglycemic events, and less time spent outside the target glucose range. The G7 represents the most accessible path to those benefits in 2025.

Frequently Asked Questions